GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipigon Pharmaceuticals AB (STU:9RP) » Definitions » Other Gross PPE

Lipigon Pharmaceuticals AB (STU:9RP) Other Gross PPE : €0.00 Mil (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Lipigon Pharmaceuticals AB Other Gross PPE?

Lipigon Pharmaceuticals AB's Other Gross PPE for the quarter that ended in Sep. 2024 was €0.00 Mil.


Lipigon Pharmaceuticals AB Other Gross PPE Historical Data

The historical data trend for Lipigon Pharmaceuticals AB's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipigon Pharmaceuticals AB Other Gross PPE Chart

Lipigon Pharmaceuticals AB Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Gross PPE
Get a 7-Day Free Trial - - - - -

Lipigon Pharmaceuticals AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Lipigon Pharmaceuticals AB Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Lipigon Pharmaceuticals AB Business Description

Traded in Other Exchanges
Address
Tvistevagen 48 C, Umea, SWE, 90736
Lipigon Pharmaceuticals AB develops medicines for diseases caused by disorders of the body's handling of fats. It focuses on orphan drugs for unusual diseases where there is no adequate treatment.

Lipigon Pharmaceuticals AB Headlines

No Headlines